Nurix Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
Nurix Therapeutics Current Ratio Growth & History (NRIX)
Nurix Therapeutics's current ratio was 7.02 for fiscal 2025.
View full Nurix Therapeutics company overviewNurix Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | 7.02 | 0.56 | +8.60% |
| 2024 | 2024-11-30 | 6.46 | 3.06 | +90.15% |
| 2023 | 2023-11-30 | 3.40 | −1.11 | −24.60% |
| 2022 | 2022-11-30 | 4.51 | −0.19 | −4.01% |
| 2021 | 2021-11-30 | 4.70 | −2.00 | −29.92% |
| 2020 | 2020-11-30 | 6.70 | 4.26 | +174.75% |
| 2019 | 2019-11-30 | 2.44 | — | — |
Nurix Therapeutics quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | 6.34 | −0.48 | −7.00% |
| Q1 2026 | 2026-02-28 | 6.01 | −0.25 | −4.01% |
| Q4 2025 | 2025-11-30 | 7.02 | 0.56 | +8.60% |
| Q3 2025 | 2025-08-31 | 5.35 | 0.07 | +1.24% |
| Q2 2025 | 2025-05-31 | 6.82 | 1.24 | +22.28% |
| Q1 2025 | 2025-02-28 | 6.26 | 3.40 | +118.71% |
| Q4 2024 | 2024-11-30 | 6.46 | 3.06 | +90.15% |
| Q3 2024 | 2024-08-31 | 5.28 | 0.93 | +21.28% |
| Q2 2024 | 2024-05-31 | 5.57 | 1.56 | +38.87% |
| Q1 2024 | 2024-02-29 | 2.86 | −1.58 | −35.55% |
| Q4 2023 | 2023-11-30 | 3.40 | −1.11 | −24.60% |
| Q3 2023 | 2023-08-31 | 4.36 | −0.90 | −17.12% |
| Q2 2023 | 2023-05-31 | 4.01 | −0.21 | −4.94% |
| Q1 2023 | 2023-02-28 | 4.44 | 0.20 | +4.65% |
| Q4 2022 | 2022-11-30 | 4.51 | −0.19 | −4.01% |
| Q3 2022 | 2022-08-31 | 5.26 | −1.82 | −25.67% |
| Q2 2022 | 2022-05-31 | 4.22 | −4.24 | −50.09% |
| Q1 2022 | 2022-02-28 | 4.25 | −2.23 | −34.45% |
| Q4 2021 | 2021-11-30 | 4.70 | −2.00 | −29.92% |
| Q3 2021 | 2021-08-31 | 7.07 | −1.80 | −20.33% |
| Q2 2021 | 2021-05-31 | 8.46 | — | — |
| Q1 2021 | 2021-02-28 | 6.48 | — | — |
| Q4 2020 | 2020-11-30 | 6.70 | 4.26 | +174.75% |
| Q3 2020 | 2020-08-31 | 8.88 | — | — |
| Q4 2019 | 2019-11-30 | 2.44 | — | — |
Nurix Therapeutics current ratio trends
Over the last five fiscal years, Nurix Therapeutics's current ratio increased from 6.70 to 7.02, a change of 0.32. The latest reported quarter, Q2 2026, shows 6.34.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nurix Therapeutics source filings ↗